Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Rivaroxaban approved in Japan for patients with PAD after revascularisation

It´s the first trial to demonstrate the benefits of dual pathway inhibition

Roche launches three new Factor Xa inhibitor coagulation tests

The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention

AstraZeneca Pharma India receives permission to import new drug

The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors

Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding